CARM — Carisma Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.01m
- -$2.77m
- $19.63m
U.S. RESEARCH ROUNDUP- Axonics, Chipotle Mexican Grill, ResMed
Brief: Modernatx Inc Reports 12.57% Passive Stake Carisma Therapeutics Inc As Of March 7 - SEC Filing
Brief: Carisma Therapeutics Closes Merger With Sesen Bio
Brief: Sesen Bio Reports Fourth Quarter And Full-Year 2022 Financial Results
Sesen Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Sesen Bio Got Determination From Nasdaq That Co Granted An Exception From Its Non-Compliance With $1 Bid Price Requirement
Sesen Bio Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Glass Lewis Joins ISS To Recommend Sesen Bio Stockholders To Approve Pending Merger With Carisma
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Sesen Bio Stockholders Vote “For” All Proposals At March 2 Special Meeting
Brief: Sesen Bio And Carisma Therapeutics Announce Increased Special Cash Dividend And Stockholder Support For Pending Merger
Brief: Sesen Bio Receives Nasdaq Delisting Notice
Brief: Sesen Bio Reiterates Confidence That Pending Merger With Carisma Is In Best Interests Of Stockholders
Brief: Investor Group Issues Letter To Boards Of Sesen Bio And Carisma
Brief: Sesen Bio Files Definitive Proxy Statement
Brief: Investor Group Issues Letter To Sesen Bio’s Board
Brief: Sesen Bio Reiterates Confidence In Pending Merger With Carisma Therapeutics
Brief: Investor Group Reiterates Intent To Vote Against Sesen Merger With Carisma
Sesen Bio up after raising special dividend
Brief: Sesen Bio and Carisma Therapeutics Announce Increase to Expected Special Cash Dividend